Bài báo khoa học Tập 65 Số CĐ 12 - Bệnh viện Thủ Đức 12/12/2024

23. TỔNG QUAN HỆ THỐNG VỀ HIỆU QUẢ - AN TOÀN VÀ BẰNG CHỨNG KINH TẾ DƯỢC CỦA THUỐC RITUXIMAB TIÊM DƯỚI DA SO VỚI RITUXIMAB TIÊM TRUYỀN TĨNH MẠCH Ở NGƯỜI BỆNH U LYMPHO KHÔNG HODGKIN

Châu Thị Ánh Minh1,2, Nguyễn Thị Phương Dung3,4, Ngô Việt Trinh3,4, Phạm Thị Thu Hiền3,4, Ngô Thị Ngọc Nhi3,4, Nguyễn Thị Hà3,4, Hoàng Tùng3,4, Nguyễn Thị Lan Phương3,4
1 The National Centre of Drug Information and Adverse Drug Reactions Monitoring, Ho Chi Minh City
2 Trung tâm DI & ADR Khu vực Thành phố Hồ Chí Minh
3 University of Health Sciences, Vietnam National University Ho Chi Minh City
4 Trường Đại học Khoa học Sức khỏe, Đại học Quốc gia Thành phố Hồ Chí Minh
Tác giả liên hệ: ntlphuong@uhsvnu.edu.vn
DOI: 10.52163/yhc.v65iCD12.1833
29 Lượt xem
14 Lượt tải xuống
Từ khóa
Rituximab u lympho không Hodgkin hiệu quả an toàn tổng quan hệ thống
Tóm tắt

Objective: This study synthesized evidence on the clinical and pharmacoeconomic aspects of subcutaneous (SC) versus intravenous (IV) rituximab for non-Hodgkin lymphoma (NHL).

Methods: The systematic review was performed according to the PRISMA statement. The search was processed on PubMed, Scopus, and Embase until February 26, 2023. Studies reported the safety, efficacy, or cost-effectiveness of rituximab SC compared with rituximab IV among NHL patients were eligible for the analysis.

Results: For evidence of efficacy and safety, three RCTs and one case-control study were included in the systematic review. The results showed no statistically significant difference between rituximab SC and rituximab IV in the safety or efficacy indicators for the treatment of NHL. In addition, results from eight pharmacoeconomic studies suggested that rituximab SC significantly helped shorten the time for healthcare workers as well as patients, and saved related costs compared to rituximab IV for the treatment of NHL.

Conclusions: Rituximab SC and rituximab IV were proved to be not different in terms of safety and efficacy for the treatment of NHL. This review also indicated that compared to rituximab IV, rituximab SC saved time and costs for the treatment of NHL in a hospital setting.

Tài liệu tham khảo
[1]
Global Cancer Observatory. Non-Hodgkin lymphoma 2020 [cited 2022 June 25]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkin-lymphoma-fact-sheet.pdf. Google Scholar
[2]
Bộ Y tế. Thông tư số 20/2022/TT-BYT về danh mục thanh toán thuốc hóa dược được hưởng bảo hiểm y tế. 2022. Google Scholar
[3]
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71. Google Scholar
[4]
Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272-e82. Google Scholar
[5]
Lugtenburg PA, I. Berenschot, H. Ilhan, O. Marolleau, J. P. Nagler, A. Rueda, A. Tani, M. Turgut, M. Osborne, S. Smith, R. Pfreundschuh, M. Efficacy and safety of subcutaneous Google Scholar
[6]
and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913-22. Google Scholar
[7]
Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836-42. Google Scholar
[8]
Rotkopf H, Lévy M, Copie-Bergman C, Dupuis J, Verlinde-Carvalho M, Itti E, et al. Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case-Control Comparison With Intravenous Rituximab. Clin Lymphoma Myeloma Leuk. 2021;21(1):e32-e8. Google Scholar
[9]
Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459-68. Google Scholar
[10]
Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non- Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227-33. Google Scholar
[11]
Kyriopoulos D, Tsiantou V, Papageorgiou L, Theodoropoulou F, Athanasakis KJJoCT. Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin’s Lymphoma (NHLs) in Greece. 2017;08:726-34. Google Scholar
[12]
Mihajlović J, Bax P, van Breugel E, Blommestein HM, Hoogendoorn M, Hospes W, et al. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. Clinical Therapeutics. 2017;39(6):1221-32.e4. Google Scholar
[13]
Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, et al. SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Ann Hematol. 2018;97(1):123-31. Google Scholar
[14]
Stewart DA, Boudreault JS, Maturi B, Boras D, Foley R. Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites. Curr Oncol. 2018;25(5):300-6. Google Scholar
[15]
Delgado Sánchez O, Gutiérrez A, do Pazo F, Ginés J, Martorell C, Boyeras B, et al. Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients. Clinicoecon Outcomes Res. 2019;11:695-701. Google Scholar
[16]
Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma. PLoS One. 2022;17(1):e0261336. Google Scholar